The current non-interventional study (NIS) was designed to document effectiveness and safety of first-line dual HER2 blockade plus chemotherapy in routine clinical practice (hospital or outpatient setting) in patients with advanced HER2+ BC relapsing after prior (neo)adjuvant T, a patient group at a principally higher risk of disease progression. Here, ERBB2 is linked to breast cancer.